Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
The efficacy of fenofibrate ( FEN ) , rosiglitazone ( RSG ) , or a calorie-restricted diet ( CRD ) to reduce cardiovascular disease risk was compared in 37 overweight/obese insulin-resistant nondiabetic subjects .  Insulin sensitivity , fasting lipids and lipoproteins , and postpr and ial plasma glucose , insulin , free fatty acid , and triglycerides were measured before and after 3 months of treatment with FEN , RSG , or CRD .  Weight decreased in the CRD group , but did not change significantly after treatment with either drug . Insulin sensitivity improved significantly in the CRD- and RSG-treated groups , but to a greater extent in those administered RSG , without a significant difference comparing FEN treatment with the CRD . Total cholesterol was significantly lower after FEN and CRD treatment . Fasting plasma triglycerides decreased significantly in the FEN- and CRD-treated groups , but postpr and ial concentrations decreased in only FEN-treated subjects . Significant decreases in postpr and ial glucose and insulin were seen in only the RSG- and CRD-treated groups . FEN administration improved dyslipidemia in these subjects without changing insulin sensitivity , whereas insulin sensitivity was enhanced in RSG-treated patients without improvement in dyslipidemia . Weight loss in the CRD group led to improvements in both insulin sensitivity and dyslipidemia , but the change in the former was less than in RSG-treated patients , and improvement in lipid metabolism not as great as with FEN . In conclusion , there did not appear to be 1 therapeutic intervention that effectively treated all metabolic abnormalities present in these patients at greatly increased risk of cardiovascular disease
Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .